Consistent with the elevated expression observed in glioblastoma tumors and an oncogenic function, our studies revealed that ADAR3 expression in glioblastoma cells leads to elevated NF-κB activation which can confer both downstream gene expression changes and cellular consequences, including increased resistance to temozolomide. This evidence concerns the gene ADARB2 and glioblastoma.